Scleroderma Diagnostics and Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Apr 2018| TMR534A| Transparency

Report Highlights

Global Scleroderma Diagnostics and Therapeutics Market: Overview

The scleroderma diagnostics and therapeutics market report studies the scleroderma diagnostics and therapeutics market globally as well as regionally for the forecast period from 2017 to 2024. The report provides valuable insights into the growth of the said market, wherein revenue estimates are presented in US$ Mn and volume estimates in Kilo tons.

Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various scleroderma drugs as well as new entrants planning to enter this market.

Included in the study is a detailed discussion on vital market indicators, which include demand drivers, challenges, and opportunities. The impact of these indicators on the scleroderma diagnostics and therapeutics market over the aforementioned forecast period have been ascertained as well. Furthermore, the report also examines growth trends and technological advancements that are likely to have a bearing on the growth of scleroderma diagnostics and therapeutics market between 2017 and 2024.

Following this, the report discusses value chain analysis to throw light on demand supply dynamics in the scleroderma diagnostics and therapeutics market. Industry-centric analytical tools such as SWOT analysis and Porter’s five forces have been employed for insights into the competitive landscape of the scleroderma diagnostics and therapeutics market. In addition, the report presents market attractiveness analysis wherein key segments within drug class, indication, test type, and geography have been identified and analyzed for their growth behavior.

Global Scleroderma Diagnostics and Therapeutics Market: Research Methodology

The report has been prepared after an elaborate primary and secondary research phase. Thus, the analysis of the scleroderma diagnostics and therapeutics market presented in reliable to a high degree. The primary research phase involved carrying out telephonic as well face-to-face interviews with industry experts along with e-mail interactions. Primary research represent major part of research efforts along with a secondary research phase. Industry stakeholders who participated in the primary research phase include CEOs, VPs, market intelligence managers, marketing/product managers, and national sales managers. Purchasing managers, technical experts, suppliers and traders were some other stakeholders who were reached out in the primary research phase. Rheumatologists, dermatologists, and physicians treating scleroderma patients were also reached out in the primary research phase of the making of the report.

Secondary research phase involved reaching out to industry-centric databases for data collection followed by data scrutiny. Secondary sources reached out include key players’ product literature, annual reports, relevant business documents, and trade journals. Some other secondary sources reached out include trade journals, technical writings, government websites, trade associations, Internet sources, and online paid databases.

Secondary research sources reached out for the study include stock analyst websites, company website sources, governmental organizations and public portals, Orange Book – FDA, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Clinicaltrials.gov, Clinicaltrialsregister.eu, journals and other publications.

  • Table 1 : Overview of active clinical trials for scleroderma
  • Table 2 : Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 3 : Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
  • Table 4 : Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2024
  • Table 5 : North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 6 : North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
  • Table 7 : North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 8 : Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 9 : Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024s
  • Table 10 : Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 11 : Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 12 : Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
  • Table 13 : Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 14 : Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 15 : Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
  • Table 16 : Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 17 : Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 18 : Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
  • Table 19 : Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 20 : Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Region, 2016–2024
  • Table 21 : Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
  • Table 22 : North America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
  • Table 23 : Europe Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
  • Table 24 : Asia Pacific Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
  • Table 25 : Latin America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
  • Table 26 : Middle East & Africa Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
  • Figure 1 : Global Scleroderma Therapeutics Market Size (US$ Mn) and Forecast, 2016–2024
  • Figure 2 : Global Scleroderma Diagnostics Market Size (US$ Mn) and Forecast, 2016–2024
  • Figure 3 : Scleroderma Therapeutics Market Value Share by Drug Class (2016)
  • Figure 4 : Scleroderma Therapeutics Market Value Share by Indication (2016)
  • Figure 5 : Scleroderma Therapeutics Market Value Share by Region (2016)
  • Figure 6 : Scleroderma Diagnostics Market Value Share by Test Type (2016)
  • Figure 7 : Global Scleroderma Therapeutics Market Value Share Analysis, by Indication Type, 2016 and 2024
  • Figure 8 : Global Localized Scleroderma Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 9 : Global Systemic Scleroderma Market Revenue US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 10 : Scleroderma Therapeutics Market Attractiveness Analysis, by Indication Type, 2015
  • Figure 11 : Global Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
  • Figure 12 : Global Corticosteroids Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 13 : Global Immunosuppressive Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 14 : Global Endothelin Receptor Agonists Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 15 : Global Calcium Channel Blockers Market Revenue ((US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 16 : Global PDE-5 Inhibitors Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 17 : Global Chelating Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 18 : Global Prostacyclin Analogs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 19 : Global Other Scleroderma Drugs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024
  • Figure 20 : Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
  • Figure 21 : Global Scleroderma Therapeutics Market Value Share Analysis, by Region, 2016 and 2024
  • Figure 22 : Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015
  • Figure 23 : North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 24 : North America Scleroderma Therapeutics Market Size and Y-o-Y Growth Projections, 2015–2024
  • Figure 25 : North America Scleroderma Therapeutics Market Attractiveness Analysis, by Country, 2015
  • Figure 26 : North America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 26 : highlights the estimated and forecast market value share of the drug class segments for 2016 and 2014
  • Figure 27 : North America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
  • Figure 28 : North America Scleroderma Therapeutics Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 29 : North America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
  • Figure 30 : North America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
  • Figure 31 : Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 32 : Europe Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
  • Figure 33 : Europe Market Attractiveness Analysis, by Country, 2015
  • Figure 34 : Europe Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 35 : Europe Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
  • Figure 36 : Europe Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 37 : Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
  • Figure 38 : Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
  • Figure 39 : Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 40 : Asia Pacific Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
  • Figure 41 : Asia Pacific Market Attractiveness Analysis, by Country, 2015
  • Figure 42 : Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 43 : Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
  • Figure 44 : Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 45 : Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
  • Figure 46 : Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
  • Figure 47 : Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 48 : Latin America Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
  • Figure 49 : Latin America Market Attractiveness Analysis, by Country, 2015
  • Figure 50 : Latin America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 51 : Latin America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
  • Figure 52 : Latin America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 53 : Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
  • Figure 54 : Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
  • Figure 55 : Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 56 : Middle East & Africa Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
  • Figure 57 : Middle East & Africa Market Attractiveness Analysis, by Country, 2015
  • Figure 58 : Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 59 : Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
  • Figure 60 : Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 61 : Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
  • Figure 62 : Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
  • Figure 63 : Global Skin Biopsy Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
  • Figure 64 : Global Imaging Techniques Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
  • Figure 65 : Global Prostacyclin Analogues Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
  • Figure 66 : Global Electrocardiogram & Echocardiogram Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
  • Figure 67 : Global Pulmonary Function Tests Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
  • Figure 68 : Global Scleroderma Diagnostics Market Attractiveness Analysis, by Test Type, 2015
  • Figure 69 : Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report